secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verastem, Inc. (VSTM)
CIK:        0001526119
Form:       8-K
Filed at:   2023-07-12T23:59:59+00:00
Accession:  0001104659-23-080188
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Verastem Oncology CEO Stuglik retires; President Paterson appointed CEO effective Aug 1
--------------------------------------------------------------------------------

- CEO Brian Stuglik retires effective July 31, 2023; receives $421,850 cash bonus.
- President Dan Paterson appointed President and CEO effective August 1, 2023; also joins Board.
- Paterson has 30+ years experience, led acquisition of avutometinib; company moving toward FDA approval in LGSOC.
- Stuglik remains on Board and chairs new Commercialization Committee.
- Committee members Kapur and Tollefson; annual retainers $10k, chair $20k.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1526119/000110465923080188/0001104659-23-080188-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1526119/000110465923080188/tm2321108d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-080188

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer